Sydney, April 27, 2026, 02:04 AEST
Cochlear Limited faces a rough start on the ASX this Monday. Shares wrapped up Friday at A$97.35—a staggering 42.21% slide over the past week—as investors continued to punish the hearing-implant maker on the heels of a major profit warning. With ASX Trade open for business Monday despite the NSW ANZAC Day public holiday, Cochlear’s performance will again be under scrutiny before normal hours kick in.
The selloff stings, given Cochlear’s reputation as a defensive play in med-tech growth. That assumption’s under pressure after the latest update—turns out implant demand, notably from adults and older patients, is more sensitive to household finances, hospital bandwidth, and clinic referrals than investors seemed to expect.
Cochlear slashed its FY26 underlying net profit outlook, now projecting A$290 million to A$330 million, a sharp reduction from the A$435 million to A$460 million it guided for earlier. The company flagged second-half sales growth of just 2% to 6% on a constant currency basis—so, that’s before factoring in forex moves.
The company reported no growth in developed-market implant revenue for the third quarter. U.S. procedure volumes slipped in March, and referrals from the hearing-aid channel also dropped off. Surgery numbers in Western Europe came under pressure, with waiting lists piling up in the UK and Germany, while strikes in Italy and Spain added to the squeeze, according to the company.
Chief Executive Dig Howitt described adult and senior hearing loss as “discretionary intervention,” pushing for Cochlear’s treatments to be recognized as an “important health priority.” Cochlear reported solid uptake for its Nucleus Nexa system, saying market share was on the rise following the wrap-up of contracting for the new product. Cochlear Assets
Pressure isn’t limited to wealthier markets. Cochlear flagged a string of issues: order cancellations and shipping slowdowns linked to the Middle East conflict, softer premium-tier demand in China following reimbursement policy changes, possible receivables provisions of as much as A$10 million, and a restructuring bill in the A$18 million to A$25 million range. Add to that about A$25 million in after-tax FX headwinds, driven by strength in the Australian dollar.
Cochlear shares tanked 40.7% on Wednesday, ending the session at A$99.58—a level not seen since March 2016—after the company’s fresh guidance landed far short of the A$402.5 million Visible Alpha consensus. Jefferies analysts questioned if the problems go deeper than just postponed volume, hinting at possible structural trouble.
Analysts and fund managers aren’t mincing words. Anna Milne from Wilson Asset Management called the size of the cut and the uncertain recovery “really shocked the market.” Jarden’s Steve Wheen said the downgrade was “far worse than anticipated.” Sacha Krien at E&P highlighted shaky volumes in developed markets, ongoing uncertainty in emerging markets, tighter margins, and the bite from restructuring costs. Wilson Asset Management
Competition is making headlines again. Wheen pointed to renewed pressure from MED-EL and Advanced Bionics, noting Cochlear’s price edge in the U.S. is slipping—the company hasn’t seen any boost in reimbursement for its device, according to the AFR report republished by Wilson Asset Management.
Shane Ponraj at Morningstar slashed his fair value estimate on Cochlear by 51%, bringing it down to A$110. He flagged “headwinds appeared more structural,” and said the company is now looking at “lower earnings growth for longer.” Still, Morningstar called Cochlear the leading player in developed-market cochlear implants, holding about 60% market share. Morningstar
The update wasn’t all gloom. Services revenue climbed 13% in constant currency for the third quarter, driven by a bigger installed base and processor upgrades. Acoustics revenue also increased, up 11%, as the Osia and Baha rollouts gathered steam.
The main worry: sluggish referrals and postponed surgeries might stick around longer than hoped. If adults and seniors continue putting off implant procedures, Cochlear’s profit hit could drag on beyond just a tough second half. On the flip side, a rebound in patient confidence and smoother hospital operations could see those waitlists eventually translate into pent-up demand.
Right now, management is slashing expenses but still backing investment aimed at adults and seniors. “Clinical need” for implants keeps rising, Howitt said. Even so, investors are likely to wait for hard evidence—orders ticking up, more referrals, higher surgery volumes—before Cochlear sees its former premium restored.
